Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Compare yields across Ex Us dividend ETFs to see which funds currently offer the highest income potential and sustainable payouts.
27,628 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
A new mobile AI for health claims to run entirely on your device, delivering medical insights faster and with far les...
A Qatar-linked LNG carrier crossed Hormuz, the first export through the strait since the war intensified. The move co...
Strategy Just Made Smallest Bitcoin Purchase In 2026, buying 535 BTC for about $43 million, signals a potential shift...
California Governor Gavin Newsom unveils a $350 billion budget designed to erase deficits, broaden reserves, and prot...
A notable fund sold millions of dollars’ worth of shares as this obesity drug stock jumped on Phase 3 momentum. Here’...
A major asset manager boosted its stake in Boot Barn, signaling confidence in the westernwear retailer. This piece br...
Researchers report clues that AI seems turn marxist after heavy workloads, raising questions for workers and investor...
Astera Labs has captured investor attention with a strong rally. This article dives into the reasons behind the move,...
The AI investment surge captured headlines and portfolios alike, but the rally isn’t smooth sailing. This article exp...
Public scrutiny can spill over into family finances. This article examines Gary Coleman’s ex-wife faces renewed quest...
ECB board member Isabel Schnabel presses for a digital euro to counter stablecoin risks, signaling tighter regulation...